Free Trial

Sumitomo Mitsui Trust Group Inc. Sells 14,224 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Ionis Pharmaceuticals logo with Medical background

Sumitomo Mitsui Trust Group Inc. cut its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 9.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 142,433 shares of the company's stock after selling 14,224 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.09% of Ionis Pharmaceuticals worth $4,297,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in IONS. Moisand Fitzgerald Tamayo LLC bought a new stake in Ionis Pharmaceuticals during the 1st quarter worth approximately $151,000. Exchange Traded Concepts LLC lifted its position in shares of Ionis Pharmaceuticals by 1,722.5% in the 1st quarter. Exchange Traded Concepts LLC now owns 3,244 shares of the company's stock worth $98,000 after purchasing an additional 3,066 shares during the period. Fifth Third Bancorp lifted its position in shares of Ionis Pharmaceuticals by 4.8% in the 1st quarter. Fifth Third Bancorp now owns 9,989 shares of the company's stock worth $301,000 after purchasing an additional 458 shares during the period. GAMMA Investing LLC lifted its position in shares of Ionis Pharmaceuticals by 3,786.5% in the 1st quarter. GAMMA Investing LLC now owns 28,993 shares of the company's stock worth $961,000 after purchasing an additional 28,247 shares during the period. Finally, California State Teachers Retirement System lifted its position in shares of Ionis Pharmaceuticals by 6.1% in the 4th quarter. California State Teachers Retirement System now owns 133,902 shares of the company's stock worth $4,681,000 after purchasing an additional 7,722 shares during the period. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Stock Performance

NASDAQ:IONS traded down $0.61 on Friday, reaching $42.98. 1,335,953 shares of the company's stock were exchanged, compared to its average volume of 1,604,922. The company has a debt-to-equity ratio of 2.63, a current ratio of 9.66 and a quick ratio of 9.62. The firm has a market cap of $6.84 billion, a price-to-earnings ratio of -14.37 and a beta of 0.23. Ionis Pharmaceuticals, Inc. has a 52 week low of $23.95 and a 52 week high of $52.34. The stock has a fifty day simple moving average of $35.24 and a 200-day simple moving average of $33.10.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.93) EPS for the quarter, beating analysts' consensus estimates of ($1.07) by $0.14. Ionis Pharmaceuticals had a negative net margin of 63.65% and a negative return on equity of 91.85%. The company had revenue of $132.00 million during the quarter, compared to analyst estimates of $144.31 million. During the same period last year, the business earned ($0.98) earnings per share. Ionis Pharmaceuticals's revenue was up 10.9% compared to the same quarter last year. As a group, sell-side analysts predict that Ionis Pharmaceuticals, Inc. will post -3.5 earnings per share for the current year.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Michael R. Hayden purchased 15,000 shares of the firm's stock in a transaction on Thursday, May 1st. The shares were purchased at an average cost of $31.86 per share, with a total value of $477,900.00. Following the completion of the purchase, the director owned 50,219 shares of the company's stock, valued at $1,599,977.34. The trade was a 42.59% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 2.71% of the company's stock.

Analyst Upgrades and Downgrades

IONS has been the topic of a number of research reports. HC Wainwright reiterated a "buy" rating and set a $50.00 target price on shares of Ionis Pharmaceuticals in a research report on Thursday, June 26th. Redburn Atlantic initiated coverage on shares of Ionis Pharmaceuticals in a research report on Monday, March 31st. They set a "neutral" rating and a $39.00 target price on the stock. Wall Street Zen upgraded shares of Ionis Pharmaceuticals to a "sell" rating in a research report on Tuesday, March 18th. Barclays upgraded shares of Ionis Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $51.00 to $57.00 in a research report on Tuesday, July 1st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a "neutral" rating in a report on Thursday, June 12th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $58.25.

Check Out Our Latest Report on Ionis Pharmaceuticals

About Ionis Pharmaceuticals

(Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Featured Articles

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Should You Invest $1,000 in Ionis Pharmaceuticals Right Now?

Before you consider Ionis Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ionis Pharmaceuticals wasn't on the list.

While Ionis Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines